Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ruxolitinib’s for MF and Potential in ET Reviewed

Blood; ePub 2017 May 12; Bose, Verstovsek

Since its approval in 2011, the Janus kinase (JAK) 1/2 inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis, and its use in patients with hydroxyurea resistant/intolerant polycythemia vera is steadily increasing, according to a recent review.

The authors note that a number of other JAK2 inhibitors have entered clinical testing, but, given the proven safety and efficacy of ruxolitinib, it is likely that ruxolitinib-based combinations will be a major way forward in drug development for myelofibrosis. They also point out that ruxolitinib is in late phase clinical trials in essential thrombocythemia.


Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: What is next? [Published online ahead of print May 12, 2017]. Blood. doi:10.1182/blood-2017-04-742288.